GLOBAL BIOANALYSIS CONSORTIUM

Regulated Bioanalysis
A Proposed Global Harmonization Process

presented by Philip Timmerman, for GBC
at 2nd JBF meeting,
March 2012, Tokyo - Japan
Outline

1. Historic perspective on the evolution of Regulated Bioanalysis
2. Recap on GBC goals and structure.
3. Update on harmonization team activities
   Summaries from January 2012
1. Historic perspective on the evolution of Regulated Bioanalysis
The early years of regulations

- 1965: EEC 65/65 (reaction to Thalidomide)
  - No real focus on bioanalysis
- 1978: 21 CFR 58
- 1982: OECD 1
  - Both are General GLP guidelines (preclinical safety)
  - Quality system ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity pre-clinical safety tests.

Eighties (flowing over in the Nineties)
- Increased focus on Bioequivalence studies (including paragraphs on bioanalytical methodology to be applied)
- EU, FDA, Australia, Canada to lead

BMV workshop – (Crystal City-I):
- < 1990 = lack of uniformity in industry wrt validation bioanalytical methods
- Crystal City-I was first international conference with focus on Bioanalytical method validation and sample analysis
Crystal City Conferences:

- CC-I
- CC-II
- CC-III
- CC-ISR

1990

Conference papers (CP):

- Crystal City I CP (Shah Paper)
- CC II CP Shah (chrom.) Miller (LBA)
- CC III CP Viswanathan
- CC-ISR CP Fast

2000

Additional white papers:

- DeSilva
- 2001 FDA Guidance

2010

Regulatory Guidance:
A. scientist adopting home designed quality systems
B. scientist shopping for inspiration in other areas – peers, DIN, EPA,..
C. scientist regrouped around Shah paper
D. multiple countries issuing regulations of BA included in BE guidelines
E. Industry increase frequency on coming together (e.g. APA, EBF, CVG) some issue recommendation papers after (broad) internal discussions

The broader and global context
The broader and global context: more detail

A. scientist adopting home designed quality systems
B. scientist shopping for inspiration in other areas – peers, DIN, EPA,..
C. scientist regrouped around Shah paper
D. multiple countries issuing regulations of BA included in BE guidelines
E. Industry increase frequency on coming together (e.g. APA, EBF, CVG) some issue recommendation papers after (broad) internal discussions
Technology developments

1960
TLC Immunoassays
bioassays
mcg/mL

1970
TLC, GC
(LC-UV) immunoassays
Sub mcg/mL

1980
GC², GC-MS
GC-NPD/ECD
HPLC-UV/fl
immunoassays
ng/mL

1990
GC², GC-MS
GC-NPD/ECD
HPLC-UV/fl
immunoassays
Sub ng/mL

2000
LC-MS/MS,
New generation
Binding assays
AMS
ICP-MS
pg/mL

2010
New generation
LC and MS/(MS)
and Binding
assays
Sub pg/mL?

2020
Highlights from technology

- Manual low throughput → automated high throughput
- MCG limits of quantification → sub-pg limits of quantification
- Chromatography: Multiple assay formats → 1 single assay format (LC-MS/MS)
- LBA: Limited assay formats → multiple (and novel) assay formats
- Paper raw data → electronic raw data
- PK of unchanged drug → PK/PD, TK, metabolites, biomarkers,..
Other factors...

Evolutions in the Pharma landscape around the turn of the century and how it (may have) impacted regulated bioanalysis across industry:

- **Portfolio changes in industry: new targets, new disease models**
  - Increased development time for small molecule scaffold → less NCE
  - Increased emphasis on peptides and proteins → more NBE
    - Enabling also faster development from Discovery to market
    - Creating a boost in (new and innovative) LBA developments

- **Patent expirations (of multi-billion dollar/Euro selling drugs):**
  - R&D optimise life cycle management
    - More Bioequivalence (BEQ) studies filed from R&D Pharma
  - Generic Pharma boosting
    - More BEQ studies (with bioanalysis often outsourced) filed from generic Pharma
  - Economic pressure on R&D Pharma calling for re-organisations resulting in more (bioanalytical) outsourcing
  - CROs growing their business exponentially (also outside EU/US)
    - More people involved = more difference in how quality is achieved and documented
    - More regions involved
Back to Bioanalysis...
On the way from CC-I to CC-II, a lot of bioanalytical experience was built.

(Re-)united at last, or??
See next slide.
From the FDA guidance onwards

> 2001……

- Individual interpretations of Guidance → ambiguity (individual flavors both from industry + HA inspectors (483))
- Technology developments not covered in Guidance
- Added value of new regulatory insights sometimes poorly understood (ISR, FDC,...)
- Regulatory awareness in an increasing number of regions leading to multiple interpretations of FDA guidance
- Some regions felt need for own guidelines (EMA, ANVISA)
- More bioanalysis is performed in more areas (metabolites, tissue, biomarkers, immune response,..) requires new guidance

More bioanalysis performed outside EU/US, i.e. APAC, LA urging scientist to re-unite

Increasing number of bioanalysis meetings in all regions, sparking peer discussions

Open letter to the Health Authorities from EBF, AAPS, CVG and APA (Bioanalysis, 2010)

Ligand Binding community didn’t feel their science was fully recognized in FDA Guidance (Findlay-2000, DeSilva-2003)

Industry united around one Guidance
OPEN LETTER

Request for Global Harmonization of the Guidance for Bioanalytical Method Validation and Sample Analysis

Open letter to the bioanalytical community. Sent to the US FDA/European Medicines Agency in February 2010
Can GBC re-unite towards a harmonized understanding and application of bioanalysis guidelines and convince the world?
はい、我々はできる
2. Recap on GBC goals and structure
Mission Statement

Create an all inclusive **Global Bioanalysis Consortium** (GBC) consisting of represented scientific associations with world wide influence to merge existing or emerging bioanalytical guidance to create one, **unified consensus document** that can be presented to the regulatory bodies/health authorities in various countries.
GBC: Goals and Objectives

• To bring together stakeholders from the pharmaceutical industry, contract research organizations and academia to share current understanding of bioanalysis guidelines, identify differences in these guidelines or differences in the interpretation or application thereof to routine regulated bioanalysis.

• To come forward with recommendations to Health Authorities and regulatory bodies worldwide on globally agreed best practices for Bioanalytical Method Validation (BMV) and application of such methods/technologies to the analysis of drugs of all molecular sizes in support of clinical and nonclinical studies.
GBC: Goals and Objectives

• To invite relevant stakeholders, from industry, academia, Health Authorities and regulatory bodies, to jointly discuss the GBC recommendations at a global conference(s) in order to achieve globally agreed guidelines on bioanalysis.

• Going forward, to serve as a pivot point on the continued harmonized interpretation and/or updates of globally agreed guidelines.
Organization Chart

Steering Committee (GBC-SC)

Scientific Leadership Team (GBC-SLT)

Harmonization Team # 1
Harmonization Team # 2
Harmonization Team # ‘n’
### Active Harmonization Teams

#### All Topics Common to all molecules
- **A1** Scope and regulations
- **A3** Method Transfer, partial/cross validations
- **A5** Sample Management
- **A7** Repeat analysis and ISR
- **A9** Analytical Instrument Qualification
- **A11** Biomarkers

#### Tiered approaches for method validation
- **A2** Tiered approaches for method validation
- **A4** Reference standards and reagents
- **A6** Stability
- **A8** Documentation
- **A10** New Frontiers

#### Large molecule specific run acceptance
- **L1** Large molecule specific run acceptance
- **L2** Large molecule specific assay operation
- **L3** Assay formats
- **L4** Reagents and their Stability
- **L5** Automation practices in LM bioanalysis
- **L6** Immunogenicity effect on Pk

#### Small molecule (Chromatographic Assays)
- **S1** Small molecule specific run acceptance
- **S2** Small molecule specific assay operation
- **S3** Chromatographic Run Quality Assessment

---

Global Bioanalysis Consortium
On harmonization of bioanalytical guidance
SC Sponsorship of Harmonization Teams

Team Leaders
A1: Surendra Bansal
A2: Steve Lowes
A4: Joseph Bower
A6: Nico van den Merbel
A11: Russ Weiner
A3: Ray Briggs
A5: Mike Redrup
A7: Eric Fluhler
A8: Tom Verhaeghe
A9: Chad Briscoe
A10: Bob Bethem/Chad Ray
S1: Douglas Fast
S2: Eric Woolf
S3: Stuart McDougall

SC Sponsor
Philip Timmerman
Daniel Tang
Shinobu Kudoh
Michaela Golob
Peter van Amsterdam
Shrinivas Savale
Rafael Barrientos
Mark Arnold

Team Leaders
L1: Marian Kelley
L2: Lauren Stevenson
L3: Sherri Dudal
L4: Lindsay King
L5: Scott Davis
L6: Jeff Sailstad
L11: Russ Weiner
L22: Philip Timmerman
L33: Daniel Tang
L44: Shinobu Kudoh
L55: Michaela Golob
L66: Peter van Amsterdam
L77: Shrinivas Savale
L88: Rafael Barrientos
L99: Mark Arnold

SC Sponsorship
Global Bioanalysis Consortium
On harmonization of bioanalytical guidance
Harmonization Team Objectives

HT Leaders Objectives
• Remove concepts of company or region from your thinking - you’re leading a global effort.
• Facilitate discussion, don’t push your personal agenda

Teams are to develop science-based best practices
• Recognize that consensus may not be possible. People with different views will spark vigorous discussion.
• Prevent bullying by the loudest voice. Allow and stimulate less extrovert people to share their opinion and experience.
• Recognize that some governments/regions may have regulations that are outdated or inconsistent with a science-based approach. Be prepared to defend proposals that conflict with existing regulations.

80:20 Rule
• Not all items within the Scope of the Team need to be redone, in fact 80% may already have industry-regulatory consensus
HT activities

Compile regional information on regulations and practices related to the Team’s scope
  • Share regulations with other Team
  • A lot of prework has been done

Evaluate scope list to categorize those that:
  • Are fully agreed to
  • Are generally agreed to
  • Have no agreement
HT activities

• For those that are **agreed to** write science-based language as proposed position

• For those that are **generally agreed to**, discuss differences and develop science-based position, write science-based language as proposed position

• For those that are **not generally agreed to**, prioritize the list to enable discussion on those with the greatest impact to the bioanalytical community
  • Have internal team discussions and where possible, develop recommendations
  • Where no consensus is achieved, provide arguments on both sides
  • Utilize GBC SC and other HT leaders for input

Team members should reach back to regional organizations for input
• Query regional organization membership on positions on a topic(s)
• Coordinate across Teams. Regional memberships will lose interest if frequently bombarded with requests.
HT activities

Proposals and outcome

• Write proposals in a clear and concise manner that are suitable for publication, include references to existing literature and regulations
  • As noted above, where proposal conflicts with existing regulations, additional details and discussion may be needed

• Create slide deck for communication of proposals that go into greater depth and may contain data. This will be foundation of
  • Presentations at regional meetings
  • Presentation at international meeting
  • Publications in international journals
  • Note: timing of publications in relation to international meeting
    • Targeting International meeting in last week of Sept 2012 – venue selection in EU is ongoing

• Where no consensus is achieved, provide arguments on both sides
New insights developed at GBC-SC meetings

Feedback indicates a desire for increased engagement, input and contribution from the different regions
- The current team dynamics and composition may not sufficiently engage the broader scientific community
- Open discussion

Desire to provide opportunity for regular updates on GBC progress in an open format
- The current process may lead to a significant period of ‘radio silence’
- Prevent all GBC-proposals coming as one avalanche at the global meeting, which may be too much to manage if not previewed
- Provide regulators a chance to get better understanding of activities of GBC
How will these concerns be addressed

*Move* GBC Global meeting from Q2 to Q3 2012.

*Inform* scientific, QA and regulatory community via discussions at appropriate 2011-2012 regional meetings in all 4 regions to give a flavor of the progress we are making.

- If the regional meeting can accommodate, include a GBC session in those meetings to provide update and allow input
- Invite 4-5 topic HT-L (or a regional representative from those teams) to present the progress of their teams and to share.
- Stimulate HT-SC(s) to present high level progress on other topics, with input from other HT
- Engage with meeting organizers how to optimize GBC visibility during the meeting
- Publish outcome as a rapid communication to ensure all regions connect (GBC website or “Bioanalysis”)
- Inviting organizations to provide travel assistance for speakers
Potential win-win

• Connect GBC better with the regions
  ➢ Reconnection with supporting organizations as our day to day supporters
  ➢ All regions get expanded opportunity to be involved
• Engage and inform a broader scientific community in advance of the global meeting
  ➢ Allow BA community to comment within the comfort zone of their region
  ➢ Allow BA community to comment to their regional organizations
• Provide the opportunity to publish a summary of thinking in advance of the global meeting
  ➢ Allow global community of practice to know what’s coming
  ➢ Be more engaged in the global meeting and not be caught by surprise
• Create visibility, recognition and connectivity in regions
  ➢ for HT-L and HT members
  ➢ for SC members
• Create flexibility to present on topics in need of influencing current thinking of regulators or on emerging guidelines
In practice

Identified meetings qualifying for inclusion GBC session

- Fit with respect to timing
- Fit with respect to willingness of organizers to include GBC session
- Meetings potentially qualifying – further discussion with meeting organizers needed

**NA:**
- Oct 2011: AAPS Washington USA + *Meet & Greet HTLs and SC*
- March 2012: 6th WRIB-CVG – San Antonio – USA + SC and HTLs f-2-f working session after WRIB
- May 21-23, 2012: National Biotech Conference, San Diego USA – *session planned*
- May 2012: ASMS Vancouver Canada – *presentation planned*
- July 2012: Land O’Lakes Wisconsin USA
- Sept 2012 APA Boston- USA
- Other regional meetings (e.g., DVDMG)

**EU:**
- Nov 2011: EBF - *Full session on GBC progress and team presentations* + *Meet & Greet HTLs and SC*
- June 12-13, 2012 EBF Focus meeting - Brussels - *1/2 day session on GBC progress and team presentations*
- Other regional meetings (e.g., Fabian, French GLP,..)

**APAC:**
- Feb 2012: APA India
- Mar 2012: JBF Japan
- April 2012: CPSA Shanghai, China – *presentation on GBC progress*
- Nov 2012:- 2nd APBC-CVG China
- Other regional meetings

**LA:**
- ACBio will be planned, targeted in May2012
- Other regional meetings
Proposed way forward

- **HT-L identification**
- **HT identification**
- **HT working on content working close with SLT**
- **SLT & HT f-2-f**
  - 29-30 Mar 2012
  - After WRIB
  - San Antonio
  - Consolidation and joint discussion of all topics in preparation of 1st Global Meeting
- **1st Global meeting (to be confirmed soon)**
  - 3 day conference in the EU in week of 24SEP2012

1. **Identified regional meetings**
   - Invite 4-5 topics to present the progress of their teams and to share.
   - Present high level progress on other topics
   - Get input
3. Update on harmonization team activities
   Summaries from January 2012
Which Harmonization Teams?

A1 Scope and regulations
A3 Method Transfer, partial/cross validations
A5 Sample Management
A7 Repeat analysis and ISR
A9 Analytical Instrument Qualification
A11 Biomarkers
A2 Tiered approaches for method validation
A4 Reference standards and reagents
A6 Stability
A8 Documentation
A10 New Frontiers
A2 Tiered approaches for method validation
A4 Reference standards and reagents
A6 Stability
A8 Documentation
A10 New Frontiers
A11 Biomarkers
L1 Large molecule specific run acceptance
L2 Large molecule specific assay operation
L3 Assay formats
L4 Reagents and their stability Link with tiered approach
L5 Automation practices in LM bioanalysis
L6 Immunogenicity (effect on PK).
L1 Large molecule specific run acceptance
L2 Large molecule specific assay operation
L3 Assay formats
L4 Reagents and their stability Link with tiered approach
L5 Automation practices in LM bioanalysis
L6 Immunogenicity (effect on PK).
S1 Small molecule specific run acceptance
S2 Small molecule specific assay operation
S3 Chromatographic Run Quality Assessment
S1 Small molecule specific run acceptance
S2 Small molecule specific assay operation
S3 Chromatographic Run Quality Assessment
Operating committees: HT-L

A1: Surendra Bansal
A2: Steve Lowes
A3: Ray Briggs
A4: Joseph Bower
A5: Mike Redrup
A6: Nico van den Merbel
A7: Eric Fluhler
A8: Tom Verhaeghe
A9: Chad Briscoe
A10: Bob Bethem
A11: Russell Weiner

L1: Marian Kelley
L2: Lauren Stevenson
L3: Sherri Dudal
L4: Lindsay King
L5: Scott Davis
L6: Jeff Sailstad

S1: Douglas Fast
S2: Eric Woolf
S3: Stuart Mc Dougall
## A1: Scope and Regulations

<table>
<thead>
<tr>
<th>Team members:</th>
<th>In scope</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Team lead</strong></td>
<td>– Scope and regulations for bioanalytical method validation and samples analysis</td>
</tr>
<tr>
<td>• Surendra Bansal</td>
<td>– Extent of validation before analysis of samples</td>
</tr>
<tr>
<td></td>
<td>➢ Consider Validation a continuum process</td>
</tr>
<tr>
<td></td>
<td>– Glossary</td>
</tr>
<tr>
<td><strong>Other members</strong></td>
<td></td>
</tr>
<tr>
<td>• Dafong Zhong</td>
<td></td>
</tr>
<tr>
<td>• Martin Ullmann</td>
<td></td>
</tr>
<tr>
<td>• Krzysztof Selinger</td>
<td></td>
</tr>
<tr>
<td>• Manish Yadav</td>
<td></td>
</tr>
<tr>
<td>• Tomoko Arakawa</td>
<td></td>
</tr>
<tr>
<td>• John Smeraglia</td>
<td></td>
</tr>
<tr>
<td>• Myriam Salvadori</td>
<td></td>
</tr>
<tr>
<td>• Jim Hulse</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Interdependencies with other teams</strong></td>
</tr>
<tr>
<td></td>
<td>– A2 Tiered approach for method validation</td>
</tr>
<tr>
<td></td>
<td>– All teams for glossary</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Out of scope</strong></td>
</tr>
<tr>
<td></td>
<td>– Biomarkers: Possibly include them as fit for purpose</td>
</tr>
<tr>
<td></td>
<td>➢ Depends if large molecule HT is..</td>
</tr>
</tbody>
</table>
Current status

Drafted scope for performing bioanalytical work.
- Worked on the scope and regulations for bioanalytical method validation and samples analysis
- Considered Validation as a continuum process (need to interact with team A2 for tiered approach to include the tiered approach within the scope for bioanalytical work)
- Drafted glossary from existing FDA and EMA documents. Additional terms to be added from other regulatory documents or from bioanalytical community, as necessary.
Next steps

- Interact with team A2 for tiered approach to include the tiered approach within the scope for bioanalytical work
- Send draft glossary to all HTs for their input
- Provide current summary to GBC HTs in March 2012 and take input
- Finalize by August 2012 to prepare for the GBC global meeting
A2 : Tiered Approaches To Method Validation

Team members:

Team lead
– Steve Lowes : NA
SLowes@advion.com

Other members
– Richard Hucker  EU
– Mohammed Jemal  NA
– Joe Marini  NA
– Vicinius Rezende  LA
– Ron Shoup  NA
– Puran Singhal  APAC
– Philip Timmerman  EU
– Naidong Weng  NA
– Tomoki Yoneyama  APAC
– Dieter Zimmer  EU

In scope
– Definitions of screening, qualification in relation to validation, applicable for
  • Validation/qualification of assays for all matrices
  • Tiered approach for metabolites quantification
    • Relevance to MIST
  • Biomarker assay qualification/validation

– Stability assessment in tiered approach (blood, tissue, urine, metabolites, biomarkers – as applicable..)
– Applicability of Fit-for-Purpose
– Relevance to Phase of drug development

Interdependencies with other teams
– A1: Scope and Regulations
– A3: Method transfers, partial/cross validations
– A10: New Frontiers
– A11: Biomarkers
– S1: Small molecule specific run acceptance

Out of scope
– Bioanalytical assays for non-regulatory data
1. Establishing Categories of Method “Validation”: Terminology
   • Screening/ Research/Qualified and Validated
   • Fit for Purpose (FFP) vs. Tiered Approaches
     – FFP the domain of biomarker assays
     – Value in differentiation from FFP
   • Tiered Approaches: Small Molecule LC/MS vs. Large Molecule LBA (e.g. immunogenicity)
   • Alternate Terminology
     – Method Performance Characterization
     – Method Establishment

2. Establishing Framework to Accommodate Tiered Approaches
   • Use of Method Establishment Plans
   • Defining key elements of each category
   • Formulating decision tree(s) around multi-tier proposal
     • i.e. Help determine “When to use what tier”

3. Considerations of Implementation of Proposed Approaches
   • By Regulatory Authorities – Globally
   • By Bioanalytical Scientists
   • By Drug Development teams
Next steps

• Formulating communication of our progress

• Reaching out to other groups to test acceptance of where we are headed

• Touch base with key “opinion-leader” regulatory people to see if we are on right track.
## A3: Method Transfer, partial and cross validation

### Team members:

**Team lead**
- Ray Briggs EU  
  raybriggs@tiscali.co.uk

**Other members**
- Richard Abbott EU
- Margarete Brudny-Kloeppel EU
- Patrick Duchene EU
- Jan Busch NA
- Bob Nicholson NA
- Naidong Weng NA
- Faye Vazaei NA
- Mahesh Kuma APAC
- Masanari Mabuchi APAC
- Paulo Galvinas LA
- Pei Hu APAC

### In scope
- Life cycle of a method after first full validation or relation with other validated methods.
  - Partial validation
  - Method transfer
  - Cross validation
- Definitions of method transfer, partial and cross validations
- Recommendation on when to perform method transfer, partial and cross validations
- Specific requirements for the transfer, partial validation and cross validation of small and large molecules
- Recommendations of which experiments are desirable for each proposed steps after full validation
- Recommendations of acceptance criteria for cross validations and method transfers
- Use of quality control material and incurred samples for transfer, partial validation and cross validation
- Pre assessment activities in method transfer and their importance to successful transfer

### Out of scope
Scope will be limited to PK analyses only at this time

### Interdependencies with other teams
- L1, S1, A2, A6, A7
Current status

- Subteams have completed drafts of sections on Partial Validation, Cross Validation and Method Transfer
- These have been individually reviewed by the team
- A consolidated single document has been prepared
- This is currently being reviewed to ensure consensus agreement and that it is consistent with current regulations in each region.
Next steps

• Complete review of Consolidated A3 document (Jan-Feb)
• Prepare slides summarising current thinking for March Meeting and share with Team Sponsors and GBC SC (Feb-Mar)
### A4: Reference standards and reagents

#### Team members:

**Team lead**
- Joseph Bower NA
  
  [Joseph.Bower@covance.com](mailto:Joseph.Bower@covance.com)

**Other members**
- Andrew Warren EU
- Carl Watson EU
- Jennifer McClung NA
- Kathy Wright NA
- Katia Pastre LA
- Mónica Cedrés Ercoli LA
- Takahiko Osumi APAC

#### In scope

- Recommendations for content in Certificate of Analysis (COA) or equivalent documentation to be included with material if COA is not available for:
  - Reference Standards
  - (small and large molecules)
  - Biomarkers
  - Metabolites
  - Internal Standards

- Recommendations for preparation of:
  - Calibration standards and QCs.
  - Stock solutions
  - Metabolites
  - Internal standards

#### Interdependencies with other teams

- L4 - Reagents and their stability – Lindsay King
- A11 – Biomarkers – Russ Weiner

#### Out of scope

- Positive controls for Immunogenicity Assays
- Bridging between lots of reference standards
• Reviewed all of the relevant regulatory guidance and industry white papers related to the content in the COA or equivalent documentation to be included for reference standards, metabolites and internal standards.

• Reviewed all of the relevant regulatory guidance and industry white papers related to the preparation of calibration standards and QCs, stock solutions, metabolites and internal standards.

• From the above, our team has generated recommendations for each and has begun to circulate to colleagues to obtain feedback:
  – The content in the COA or appropriate documentation to be included for reference standards, metabolites and internal standards.
  – The preparation of calibration standards and QCs, stock solutions, metabolites and internal standards.

• Next meeting is Jan 30th in which we will be reviewing all feedback on our recommendations.
Next steps

- Review feedback and comments from our recommendations.
- Create a final draft version to be distributed to a wider audience.
- Compile preliminary slide deck for presentation in Mar
- Adjust slide deck following feedback
- Long term – discuss how best to present our recommendations in white paper for publication
Team members:

Team lead
• Mike Redrup  EU
  mike.redrup@quotientbioresearch.com

Other members
• Harue Igarashi  APAC
• Subramanium Ramachandran  APAC
• Mohamed Ben Barak  EU
• Vera Hillewaert  EU
• Thales Cardoso  LA
• Jenny Lin  NA
• Jay Schaefgen  NA
• Tanya Boutros-Brown  NA

In scope
All aspects of sample management from collection to disposition
• Collection, handling and storage at clinical/animal lab
• Storage and shipment from clinical/animal lab to CL or analytical lab
• Pre analysis storage at analytical lab
• Post analysis storage or shipment
• Disposal or archiving/banking
• Sample management using LIMS / sample management systems

Interdependencies with other teams
A6, A10, A11

Out of scope
TBD
Current status

- Team TC’s ongoing (3 weekly intervals)
- Currently have only looked at 2/6 topics but will accelerate to at least touched each topic by San Antonio meeting in March
- Will need to re visit these topics over the next few months
Next steps

• Cover all topics by San Antonio meeting
• Prepare slides for San Antonio
• Will need to re visit all topics over the next few months before Autumn meeting. Topics will be shared by team members in sub groups.
# A6: stability

## Team members:

**Team lead**
- Nico van de Merbel – EU – merbelnicovande@praintl.com

**Other members**
- Julie Diancin NA
- Joleen White NA
- Natasha Savoie NA
- Maria Francesca Riccio LA
- Morten Kall EU
- Ronald de Vries EU
- Manish Yadav APAC
- Kelly Dong APAC
- Yoshiaki Ohtsu APAC

## In scope
- Spiked samples (biological and surrogate) and extracts
- Incurred samples and extracts
- Normal matrices (blood, plasma/serum, urine, tissue)
- Special matrices (hemolyzed, lipidemic etc)
- Presence of co-formulated and co-administered drugs, metabolites
- Stock and standard solutions, reagents
- Stability during sample collection and transport
- Stability during extraction and analysis
- Definitions and nomenclature: -70 vs -80 °C, room temperature, degradation vs stability vs solubility loss vs absorptive loss, fresh vs stored
- Design: t=0 vs nominal, fresh vs frozen standards, number of replicates, concentrations and time-points, ultra-low temperature for reference, stability in whole blood, instrument response vs concentrations
- Criteria: fixed or statistical approach
- Transferability of results: between labs and between methods

## Out of scope
- Stability assessment in tiered approach – A2
- Stability of reference standards – A4
- Stability of reagents for macromolecules – L4

## Interdependencies with other teams
- A3 (transfer of stability results)
- A4 (stability of reference standards)
- A7 (ISR and ISS)
- L1/L2 (fresh vs frozen standards)
- L4 (stability of reagents for macromolecules)
- S2 (reinjection and salt/counter-ion changes)
Current status

- Stability requirements in relevant guidelines, white papers etc have been summarized and divided into issues of high, medium and low priority.

- Owners have been defined for each of the stability-related issues.

- Owners of (four) high-priority issues have drafted recommendations and lead the discussions, which are ongoing. The documents have been reviewed and discussed and will be finalized by end of January.

- Next, issues of medium priority will be addressed in the same way.
Next steps

• Each identified stability-related issue will be addressed in the same way as done so far:
• the owner will draft a text with (1) scientific background, (2) recommendations of the team and (3) where necessary a discussion of practical issues
• These will be reviewed by the entire team, discussed in one or more TCs and finalized
• Where applicable, discussions will be held with other teams to manage overlap and streamline the output of the teams
• Eventually, all texts will need to be combined into a single document, details still need to be clarified
A7: Repeat analysis and ISR

Team members:

**Team lead**
- Eric Fluhler NA
  eric.fluhler@pfizer.com

**Other members**
- Ajai Chaudhary NA
- Bernard Jeanbaptiste EU
- Dafong Zhong APAC
- Faye Vazvaei NA
- Jignesh Bhatt APAC
- Puran Singhal APAC
- Theo de Boer EU
- Wenkui Li NA
- Oscar Alderetr LA
- Vinícius Rezende LA
- Masahiro Taniguchi APAC
- Petra Vinck EU

In scope

Repeat analysis:
- Repeats for analytical reasons
- PK repeats (Including pre-dose concentrations)
- Single analyte repeat in multi-analyte assays
- Reinjection <-> Reanalysis
- Decision trees
- Acceptance criteria
- Failure and Investigation

ISR:
- Multiple analytes & endogenous compounds
- Timing of ISR analyses
- Sample selection
- Number / percentage of ISR samples
- Types of studies
- Acceptance criteria
- Failure and Investigation
- Large molecule considerations

Interdependencies with other teams:

- Stability Team – Stability of incurred samples

Out of scope

- Run acceptance criteria, including IS response variability/issues
Current status

- Sub-teams formed to address guidance around:
  1. Repeat analysis (RA)
  2. Incurred sample reanalysis (ISR)
  3. Failures and investigations
- Sub-teams 1 & 2 have been meeting throughout Q3-Q4 2011 and established recommended principles to be applied for their topics
- Sub-team 3 initiated activities in December 2011 and is working on establishing recommendations
- Full team has reviewed output from teams 1 & 2 and provided feedback to teams.
- Verbiage drafted for guidance around classical aspects of RA and ISR
Next steps

• Continue sub-team 3 efforts on “failure and investigations”
• Establish communication with Stability team (incurred sample stability)
• Prepare preliminary slide deck for March meeting
• Obtain SC feedback on positions
• Progress sub-team output to final draft for publication
• Prepare for global meeting overview
A8: Documentation

Team members:

Team lead
- Tom Verhaeghe
  EU tverhaeg@its.jnj.com

Other members
- Eric Woolf
  NA
- Hollie Barton
  NA
- Marian Kelley
  NA
- Myriam Salvadori
  LA
- Richard Hucker
  EU
- Srinivasa Reddy
  APAC

Interdependencies with other teams
- A1: Scope and regulations for bioanalytical validation and sample analysis

In scope
- Definitions of different report types
- Method Validation reports
- Study protocol / plan
- Study reports
- Failure investigation and documentation
- Documentation at analytical site (including data generation, handling and reporting)
- Raw data definitions (electronic and paper) including chain of custody for samples and reference, standards, notebook records, instrument use, maintenance, system validation, freezer records etc
- Archiving and retrieval of data, storage period for data
- Bioanalytical summary documents ie CTD sections 2.7.1. and 2.6.5.
- Technology platforms for reports

Out of scope
- Clinical study reports
- Documentation of method development
- Harmonized template for validation and study reports
Current status

• Had six 1-hour meetings so far
• Almost done with the content of the bioanalytical study report
• Increase frequency of meetings to bi-weekly and duration to 1.5h
Next steps

• Tackle method validation report content
A9: Analytical Instrument Qualification

Team members:

Team lead
- Chad Briscoe – NA
  briscoechad@praintl.com

Other members
- Hidehisa Tachiki – APAC
- Jianing Zeng – NA
- Manish Yadav – APAC
- Katia Pastre – LA
- Petra Struwe – EU
- Ron Shoup – NA
- Scott Davis – NA
- Michael Blackburn – EU
- Ping Du – APAC

In scope
- Equipment Software Validation
- Change control/Routine requalification
- Instruments/Equipment
- System Suitability
- Holistic Approach
- Regulatory/Audits
- Role of the Laboratory and IT in Lab Software Validation

Out of scope
- IT Infrastructure Qualification
- Design Qualification
- Stand-alone/non-instrument controlling software: spreadsheets, homegrown, COTS
- LIMS, ELN where not interfacing with instruments

Interdependencies with other teams
- A1 : Scope and regulations
- A8 : Documentation
- A10 : New Frontiers
- L5 : Automation practices
- S2: Assay Operation
Current status

• Completed detailed discussion of scope topics.
  – Developed 1-2 slides of detailed discussion on each in-scope topic.
• Identified that one of the biggest areas for harmonization is terminology rather than actual approach taken.
• Reached agreement that AIQ for Regulated Bioanalysis is not the same as for GMP and we need to be sure to keep this as a key output.
Next steps

• Clean up and agree on conclusions
• Compile critical messages from all topics
• Organize into a flexible presentation.
  – Flexible in the sense of being able to adjust it to meet the interests of multiple levels of AIQ knowledge
A10: New Frontiers

Team members:

Team lead
- Chad Ray  NA LM  Chad.A.Ray@pfizer.com
- Bob Bethem  NA AMS  bob.bethem@vitaleascience.com

Other members
- Steve Dueker  NA AMS
- Mark Seymour  EU AMS
- Greame Young  EU AMS
- Philip Timmerman  EU AMS/DBS
- Chris Evans  NA DBS
- Keiko Nakai  APAC DBS
- Qin Ji  NA DBS/LM
- Leo Kirovsky  EU DBS/LM
- Jignesh Kotecha  APAC DBS/LM
- John Smeraglia  EU DBS/LM
- Hendrick Neubert  EU LM
- Ronald de Vries  EU LM
- Rick Steenwijk  NA LM
- Monica Whitmore  NA ICP/MS

In scope
- Validation Figures of Merit for each technology, e.g., LOQ
- Fit for Purpose qualification/validation requirements for each technology
- Run acceptance criteria for each technology

Out of scope
- S - Small molecule specific run acceptance, assay operation and QCs
- L – Large molecule guidelines specific to LB

Interdependencies with other teams
- A1, A2, A4, A5, A7, A8, A9, L4, L5
**Current status**

- Organized 3/4 sub-team with leaders
- Re-evaluating potential contributors to ICP/MS

<table>
<thead>
<tr>
<th>Task</th>
<th>Lead</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMS – Collecting definitions and White Paper Contributions from NA labs</td>
<td>Bob Bethem (NA)</td>
<td>Initiating</td>
</tr>
<tr>
<td>AMS – Definitions, best practices and White Paper Contributions from EU labs</td>
<td>Mark Seymour (EU)</td>
<td>Initiating</td>
</tr>
<tr>
<td>AMS – EBF Status and/or Guidelines in Development</td>
<td>Philip Timmerman (EU)</td>
<td>Initiating</td>
</tr>
<tr>
<td>Large Molecules – LM team organizing</td>
<td>Chad Ray (NA)</td>
<td>Initiating</td>
</tr>
<tr>
<td>Dried Blood Spots/Micro Sampling team organizing</td>
<td>Chris Evans (NA)</td>
<td>Initiating</td>
</tr>
<tr>
<td>ICP-MS team organizing</td>
<td>TBD</td>
<td>TBD</td>
</tr>
</tbody>
</table>
Next steps

AMS
- Survey existing White Papers and any existing precedent used by current labs, EBF etc.
- Definition of terms and validation figures of merit
- Determine Fit for Purpose validation requirements, e.g., TRA pK, absolute BA, met profiling/fingerprinting
- Develop cross referenced table to determine area of general agreement and differences in validation and data acceptance approach

Large Molecules
- Survey of next generation technologies
- Evaluate how these technologies might be incorporated into regulatory environment
- Evaluation of gaps and opportunities
- Review existing documents relating to reagent life cycle management and qualification

ICP-MS
- Definition of terms and validation figures of merit
- Review recent White Paper relative to GBC objectives and other guidelines (EBF)

DBS
- Generate survey of applications and evaluate longer term harmonization needs

General
- Review interdependencies with other teams where appropriate.
- Compile preliminary slide deck for presentation in March
A11: Biomarkers

Team members: 

Team lead 
• Russell Weiner NA russell.weiner@merck.com

Other members 
• Jean Lee NA
• Mohammed Jemal NA
• Ajai Chaudhary NA
• Ray Briggs EU
• Birgit Jaitner EU
• Yuichi Yamamoto APAC
• Dongbei Li APAC
• Invited NA
• Invited EU
• Invited APAC

In scope 
To be confirmed once team is formed 
• Fit-for-purpose assay development and validation 
• Exploratory data used for internal decision making and not to be submitted to regulatory agencies versus data to be used for making dosing decisions that will be part of the filing (e.g. modeling PK/PD data to justify dose) 
• When to use GLP versus non-GLP validation 
• GLP versus CAP/CLIA for assays performed in-house, in a clinical lab or in a clinical lab when assay has regulatory approval (510K, PMA, CE marked, etc) and/or assay is well established

Out of scope 
• TBD once team is formed

Interdependencies with other teams 
• A2: Tiered approach to method Validation 
• A4: Reference standards and reagents 
• A5: Sample management 
• L4: Reagents and their stability
Current status

• Team invitations sent 13-Jan-12
• Awaiting RSVP from 3 team members
Next steps

• Finalize team members
• Once team membership is locked-in determine what is in scope/out of scope via e-mail
• Schedule monthly telecons
# L1: Run Acceptance

## Team members:

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Team lead</td>
<td>Marian Kelley</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:mmk48@comcast.net">mmk48@comcast.net</a></td>
<td></td>
</tr>
<tr>
<td>Other members</td>
<td>Paula Kaminski</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Katsuhiko Yamamoto</td>
<td>APAC</td>
</tr>
<tr>
<td></td>
<td>Daniela Stoellner</td>
<td>EU</td>
</tr>
<tr>
<td></td>
<td>Ross Bamford</td>
<td>EU</td>
</tr>
<tr>
<td></td>
<td>Arumugam Muruganandam (Anand)</td>
<td>APAC</td>
</tr>
<tr>
<td></td>
<td>Ravi Trivedi</td>
<td>APAC</td>
</tr>
<tr>
<td></td>
<td>Samantha Little</td>
<td>EU</td>
</tr>
<tr>
<td></td>
<td>Lauren Stevenson</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Dongbei Li</td>
<td>APAC</td>
</tr>
<tr>
<td></td>
<td>Chris Beaver</td>
<td>NA</td>
</tr>
</tbody>
</table>

## In scope
- Non-linearity of standard curve
- Accuracy, precision and total error
- Fresh or Frozen QC/Standards during validation
- Identify the parameters to be used for monitoring validity of the data
- Curve editing

## Interdependencies with other teams
- L2: Assay Specific Operation
- A3: Method Transfer
- L3: Assay Formats
- S1: Small Molecule Run Acceptance

## Out of scope
- Stability of QC long term during sample analysis:
Current status

The team has discussed:

• Non-linearity of the curve
• Total Error
• Use of Fresh/Frozen calibrators and QCs
• Curve Editing
Next steps

The team still needs to discuss:

• Accuracy and Precision acceptance during validation and during sample analysis

• Which parameters are most important for accepting a method or considering a run valid
# L2: Large Molecule Specific Assay Operation

## Team members:

<table>
<thead>
<tr>
<th>Team lead</th>
<th>Other members</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Lauren Stevenson NA</td>
<td>- Clare Kinglsey EU</td>
</tr>
<tr>
<td></td>
<td>- Karolina Oesterlund EU</td>
</tr>
<tr>
<td></td>
<td>- Marian Kelley NA</td>
</tr>
<tr>
<td></td>
<td>- Heather Myler NA</td>
</tr>
<tr>
<td></td>
<td>- Boris Gorovits NA</td>
</tr>
<tr>
<td></td>
<td>- Yoshiyuki Minamide APAC</td>
</tr>
<tr>
<td></td>
<td>- Arumugam Muruganandam APAC</td>
</tr>
<tr>
<td></td>
<td>- Mario Dominguez LA</td>
</tr>
</tbody>
</table>

### In scope
- Testing of ruggedness and robustness
- Setting up a balanced validation design
- Dilution linearity
- Specificity testing
- Selectivity testing
- Parallelism
- Hook effect

### Out of scope
- Cross validation (A3)
- Approach for spiking QCs for validation (L1)
- Use of drug product, drug substance or reference standard as the entity used in validation/sample analysis (A4)

### Interdependencies with other teams
- L1 – Assay Acceptance
- A6 – Stability
Current status

- All in-scope topics have been discussed in some detail and broad agreement has been achieved
- Ongoing team and consultant discussions occurring monthly or more frequently to refine consensus
- Consensus refined and language being drafted for:
  - Robustness and ruggedness
  - Balanced validation design
- Continuing to refine consensus for:
  - Dilution linearity
  - Specificity testing
  - Selectivity testing
  - Parallelism
  - Hook effect
Next steps

- Work through details on topics requiring further discussion and complete draft language for all topics
- Goal – draft language on most if not all topics in time for 6\textsuperscript{th} WRIB (March)
L3: Assay formats

Team members:

Team lead
Sherri Dudal EU
sherri.dudal@novartis.com

Other members
• Daniel Baltrukonis NA
• John Smeraglia EU
• Karolina Osterlund EU
• Katherine McKay EU
• Mahesh Kumar APAC
• Yoshitaka Taniguchi APAC
• Alison Joyce NA
• Rebecca Crisino NA
• Jihong Yang NA
• Jaya Goyal NA

In scope
• Assay platforms for LBAs – Gyros, MSD, Biacore, AlphaLISA, Delfia, Singulex, Luminex, Immuno-PCR, ELISA (384), Cell-based assays, RIA
• Acceptance criteria for these methods for both validation and sample analysis
• How to set up the assays – placement of standards and QCs in these new formats
• Pros and cons of using these formats
• Multiplexing with these formats and criteria required

Interdependencies with other teams
• A10 New Frontiers: determine acceptance criteria for new methods Assay format is set-up in function of new technologies used.
• L1 Large molecule specific run acceptance: acceptance criteria for new methods/platforms versus ELISA 96 well plate

Out of scope
• L2: set-up of a balanced design for 96 well ELISA
• L4: stability of critical reagents
• L5: any automation activities linked to the platform
In January, each work group will present their assay platform for discussion in a larger team session:

- Each team has been formed to ease time differences and is grouped according to expertise with a particular platform.
- It is expected that once the platform issues, criteria and pros and cons are presented and discussed within the team, these will be presented to colleagues at the workplace and in forum discussion groups to obtain more feedback.
- The following organization is in place for January:

<table>
<thead>
<tr>
<th>Platform</th>
<th>Leader</th>
<th>Team member</th>
<th>Team member</th>
<th>Team presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gyros</td>
<td>Karolina (EU)</td>
<td>Sherri (EU)</td>
<td>Alison (NA-E)</td>
<td>January 16th</td>
</tr>
<tr>
<td>Cell-based assays</td>
<td>Daniel (NA-E)</td>
<td>Yoshitaka (APAC-Japan)</td>
<td>Jaya (NA-E)</td>
<td>January 30th</td>
</tr>
<tr>
<td>RIA</td>
<td>Mahesh (APAC-India)</td>
<td>Daniel (NA-E)</td>
<td></td>
<td>January 16th</td>
</tr>
<tr>
<td>384-well format</td>
<td>John (EU)</td>
<td>Karolina (EU)</td>
<td></td>
<td>January 9th</td>
</tr>
<tr>
<td>Alpha-ELISA/Delfia</td>
<td>Rebecca (NA-E)</td>
<td>Jaya (NA-E)</td>
<td>John (EU)</td>
<td>January 9th</td>
</tr>
<tr>
<td>Singulex</td>
<td>Alison (NA-E)</td>
<td>Rebecca (NA-E)</td>
<td>Mahesh (APAC-India)</td>
<td>January 16th</td>
</tr>
<tr>
<td>Biacore</td>
<td>Sherri (EU)</td>
<td>Jihong (NA-W)</td>
<td>Alison (NA-E)</td>
<td>January 23rd</td>
</tr>
<tr>
<td>MSD multiplex</td>
<td>Katherine (EU)</td>
<td>Yoshitaka (APAC-Japan)</td>
<td>Karolina (EU)</td>
<td>January 30th</td>
</tr>
<tr>
<td>Luminex multiplex</td>
<td>Jihong (NA-W)</td>
<td>Katherine (EU)</td>
<td>Jaya (NA-E)</td>
<td>January 23rd</td>
</tr>
<tr>
<td>Immuno-PCR</td>
<td>Jaya (NA-E)</td>
<td>Jihong (NA-W)</td>
<td></td>
<td>January 23rd</td>
</tr>
</tbody>
</table>
Next steps

Once each assay platform has been presented and discussed:

• A preliminary slide deck will be compiled for presentation in the various conferences of 2012 and adjusted throughout the year according to feedback.
• After each presentation, a GBC L3 team session will be organized to present the discussion points to the team.
• September goal: to publish results from assay platforms in a journal to capture the L3 team contribution.
• Long-term goal: discuss incorporation of assay platform criteria into regulatory guidelines and how this can be done through GBC. Possibly a white paper publication.
**L4: Reagents and their stability - Link with tiered approach**

**Team members:**

**Team lead**
- Lindsay King  
  NA  [Lindsay.King@pfizer.com](mailto:Lindsay.King@pfizer.com)

**Other members**
- Susanne Phil  
  EU
- Mark Ma  
  NA
- Esme Farley  
  NA
- Priya Sriraman  
  NA
- Masood Khan  
  NA
- Jeannine Keefe  
  NA
- Mami Imazato  
  APAC

**In scope: LBA Critical Reagents**

What are the critical reagents
- Ab, peptides proteins, conjugates, Drug as reagent, ADA reagents including positive and negative control.

Reagent testing
- Specificity testing
- What to do when you change critical reagents
- Batch to batch testing

Stability of reagents
- Testing
- Reagent formulation

In-house vs. commercial reagents pros and cons

Reagents and assay transfer

**Interdependencies with other teams – if any**

- **A3:** Method Transfer  
  Past Member: First line external contact
- **A4:** Reference Standards and Reagents  
  Chun Hua (Sherry)  
  NA
- **A6:** Stability
- **L2:** Large molecule specific assay operation
- **A8:** Team Documentation

**Out of scope:**

- Reference Standards
- Internal Standards
- Cell Based PK assays
- Matrix
- Commercial Kits
Current status

Sub-teams are generating Draft overviews of each sections in context of identified regulatory guidance, white papers and literature to identify gaps, areas of ambiguity/debate and potential best practices

Critical Reagents Outline and Sub-team Responsibilities

- Introduction
- What are the critical reagents: (Jeannine)
  - Antibodies, peptides, proteins, conjugates, Drug as reagent, ADA reagents including positive and negative control. (hybridization assays reagents)
- Documentation (SOP and COA); (Jeannine);
- Regulatory Landscape (Susanne, Priya, and Lindsay)
- Reagent testing (Esme and Mario)
  - Specificity testing
  - What to do when you change critical reagents
  - Batch to batch testing
- Stability of reagents (Mark and Lindsay)
  - Testing
  - Reagent formulation
- In-house vs. commercial reagents pros and cons (Masood and Mami)
- Reagents and assay transfer (Lindsay)
Next steps

• Team meetings; Feb 1, Feb 22 and March 14th
  ➢ Subteams to meet offline as needed.

• Sub Team section first draft/outlines must be complete with comments from full team by March 4

• Each sub team will then draft 2-3 slide max as high level overview of sections with any content gaps identified for review by March 13th

• At March 14th Team meeting these slide will be reviewed by full team

• Target March 21 for San Antonio meeting Slide Set
  ➢ Anticipate that this Slide set will have gaps in that will need to be addressed. These will be identified in the slide we present in San Antonio with a mid May target for completion

• March-Sept 2012: Incorporate feedback from global community. Solicit as widely as possible. Draft Final Slide set for Fall 2012 Read out.

• Draft white paper for Dec 2012
L5: Automation practices in LM bioanalysis

Team members:

Team lead
• Scott A. Davis NA
  Scott.Davis@ppdi.com

Other members
• Ago Ahene NA
• Claudio Calonder EU
• Joseph Kowalchick NA
• Takahiro Nakamura APAC
• Nouri Parya NA
• Igor Vostiar EU
• Jin Wang NA
• Yang Wang APAC

In scope
• Operational
  Includes procedural concerns.
• Electronic
  Includes concerns with electronic data and compliance.
• Instrument
  Includes concerns with instrument hardware.
• Assay
  Includes concerns with assay validation and/or verification.

Interdependencies with other teams
• A3 - Assay Transfer
• A7 – Repeat Analysis and ISR
• A9 – Analytical Instrument Qualification

Out of scope
• LIMS
• Automation application for non-regulated activities
• Large Molecule analysis using LC/MS
• Sample Preparation
Current status

An outline of our main topic headings that are being discussed.

**Operational**
- Automation Instrument & Software Validation
- System Documentation
- User Training
- Automation Issue Reporting
- Configuration Management
- Scripts
- Maintenance
- Decommissioning
- Periodic Review

**Electronic**
- User Access
- eData Security
- Compliance With Appropriate Guidance Documents
- Business Continuity

**Instrument**
- Instrument Maintenance Including Calibration/Verification
- Risk Assessment
- Validation of Interfaces

**Assay**
- Assay Accuracy & Precision Testing
- Instrument /Script Qualification for Validated Analytical Methods
Next steps

Our main discussions are complete and we are presently fine tuning our notes. A completed document including specific guidance will definitely be ready by March 2012.
L6: Anti-drug antibody (ADA) Interference of PK Assessments

Team members:

Team lead
- Jeff Sailstad NA 
  Sailstad@aol.com

Other members
- Adrienne Clement Egan NA
- Boris Gorovits NA
- Heather Myler NA
- Jason (Jay) WNAtner NA
- Lakshmi Amaravadi NA
- Lei Tang NA
- Renuka Pillutla NA
- Shobha Purushothama NA
- Joleen White NA
- Vikram Kansra NA

Scope
ADA can alter the pharmacokinetics of a therapeutic as well as interfere with the analytical methods or assays used to determine the pharmacokinetics. Since the primary expertise within our group is bioanalytical we will be discerning ways to separate true alterations of pharmacokinetics from artificial changes by interference in the analytical method. Consideration will be provided on various assay formats and relative susceptibility to ADA interference. Much of the discussion will be based upon case studies where analytical interference was suspected, either confirmed or shown not to be an issue. Where analytical interference was confirmed, examples will be given of the actions taken to address the impact on PK assessments. Once analytical interference is ruled out we will provide guidance on factors to consider in assessing the magnitude in changes to PK assessments. This will also be done using case studies where a change in pharmacokinetics can have no effect to profound changes in the pharmacodynamics and possible safety of a therapeutic. We hope to provide guidance on the factors to consider in assigning the magnitude of ADA impact on pharmacokinetics. Based on the collective experience of the team members we attempt to rank those factors.

ADA interference can impact the interpretation PK data throughout a development program therefore our scope will include pre-clinical and clinical applications.

Out of scope
- Immunogenicity Assessment
- Cut point analysis
- Screening assay
- Confirmatory assay
- Nab assay

Interdependencies with other teams
- Link with tiered approach
- Monique Putman EU

Global Bioanalysis Consortium
On harmonization of bioanalytical guidance

84
Current status

• We are currently working with a “trial balloon” outline for a white paper.

• This outline is helping the team channel our thoughts, eventually leading to a paper but at this point more importantly directing the team to area of more discussion and where additional case studies can be invoked.
Next steps

• Continue with Monthly Telecoms –
• Subdivide sections for initial draft of paper
• Outreach, starting at WRIB and continuing at NBC share high level outline and direction committee is going for input from a larger community
• Targeting having paper ready for submission approximately November 2012.
## S1: Small molecule – Specific run acceptance

### Team members:

**Team lead**
- Douglas Fast
  - NA
  - Douglas.Fast@covance.com

**Other members**
- Maristela Andraus
  - LA
- Matt Barfield
  - EU
- Michael Blackburn
  - EU
- Ben Gordon
  - EU
- David Hoffman
  - NA
- Noriko Inoue
  - APAC
- Amy LaPaglia
  - NA
- Richard LeLacheur
  - NA – Deputy Team Lead
- Gabriel Marcelin Jimenez
  - LA
- Scott Reuschel
  - NA
- Ravi Sankar
  - APAC

### In scope:

- **During validation**
  - Linearity, accuracy, precision
  - Calibration curve range and QC placement
  - Selection of regression analysis model (linear, quadratic, weighting)
  - Criteria for individual runs and overall acceptance
  - Validation of plasma blank samples
  - Cross validation of anticoagulants and counterions

- **During samples analysis**
  - Individual run acceptance
  - Internal standard criteria
  - Carryover
  - Positive control or predose samples
  - Anomalous sample results on run acceptance
  - System suitability testing
  - Sample and run reinjection
  - System conditioning

### Interdependencies with other teams:
- A2, A7, A8, A9, L1, S2, S3

### Out of scope:
- GBC: Global Bioanalysis Consortium
  - On harmonization of bioanalytical guidance

---

87
• Meeting biweekly from September through December
• Meeting weekly from January 2012
• 14 Topics identified for discussion (as shown on Slide 1)
• We, in general, favor less-prescriptive language, are in agreement with the bulk of the regulations (FDA/EMA at least), but have specific comments on almost all topics
• Have completed 8 of the 14 topics
• Have identified 3 topics encompassing system suitability and matrix conditioning that require input from or coordination with other HTs (A9, L1, S2, S3)
• Presented on progress at EBF Barcelona
Next steps

• Complete topic reviews and discussion
• Assemble draft document with recommendations
• Present at GBC HT-L meeting in San Antonio (March)
• Identify regional meetings for presentations prior to global conference and team members to attend and present
S2: Small molecule specific assay operation

Team members:

Team lead
• Eric Woolf NA
  woolf@merck.com

Other members
• Abhishek Sharma APAC
• Barbara Duncan NA
• Berthold Lausecker EU
• Gabriel Marcelin LA
• Kazutaka Togashi APAC
• Miguel Vago LA
• Pat Bennett NA
• Ravi Kumar Trivedi APAC
• Roger Hayes APAC
• Steve White EU

In scope
- Carryover and contamination
  - methodology to assess
  - acceptance criteria
  - impact of sample analysis sequence
- Sensitivity
  - “One off" std. curve range changes
- Specificity - selectivity
  - impact of co. meds/metabolites
- Matrix Effects
  - assessment methodology
  - effect of hemolyzed/hyperlipidemic plasma
- Recovery
  - assessment methodology & acceptance criteria
- IS evaluation
  - addition methodology
  - response variability assessment & acceptance criteria
- System equilibration
  - use of study samples
- Sample reinjections
- Reporting of failed runs
- Impact of salt form/counter ion changes of analyte
- Preparation of calibrators – organic solvent content

Interdependencies with other teams:
Sample reinjection – Team A6 (re: stability)
API Salt / Counter-ion changes – Team A6 (re: stability)
System Equilibration – Team A9 (re: system suitability)

Out of scope
- stability criteria
Current status

Where are we now:

1. Scope fully fleshed out and aligned with current regulatory requirements

2. Points of agreement and points of discussion for in-scope topics determined

3. Currently working through points of discussion
   - complete for 2 of 11 topics as of 9 January
Next steps

Continue working through topics with a goal to have completed the bulk of them by the time of the CVG meeting

Begin drafting text.
S3: Chromatographic Run Quality Assessment

Team members:

Team lead
- Stuart McDougall  EU
  stuart.mcdougall@covance.com

Other members
- Ravi Kumar Trivedi  APAC
- Ravi Sankar  APAC
- Chris Holliman  NA
- Hollie Barton  NA
- John Dunn  NA
- Ray Farmen  NA
- Katja Heinig  EU
- Liz Thomas  EU
- Maria Francesca Riccio  LA
- Junji Komaba  APAC

In scope
- All analytes giving a quantitative chromatographic response
- Chromatographic approaches (primarily LC)
- Chromatographic detection (primarily MS)
- Calibration and maintenance of chromatographic systems
- Signal to Noise
- Resolution & selectivity
- Peak shape
- SST
- Data sampling
- Peak smoothing & peak filtering
- Internal Standard response criteria
- General integration parameters (not vendor specific)
- Integration process (automated, semi-automated, manual)
- Reintegration (post regression)
- Chromatographic data review
- Audit trail (integration & reintegration)

Out of scope
- Specific integration parameters (vendor)
- Regression slope
- Instrument qualification

Interdependencies with other teams
- S1 Small molecule specific run acceptance (Run acceptance, IS acceptance criteria & SST)
- S2 Small molecule specific assay operation (sensitivity, specificity and selectivity)
- A9 - Analytical instrument qualification (calibration and maintenance)
- A1 - Scope and regulations (21CFR11, audit trail, glossary of terms)
Current status

- Team members have delegated subtask assigned and provides summary document (regulatory position, scientific literature, recommendation) to team in advance of regular (two-week) teleconference and WebEx meeting.
- Meeting agenda and meeting minutes distributed
- All TC’s organized until end Mar

<table>
<thead>
<tr>
<th>Task</th>
<th>Lead</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calibration and maintenance of chromatographic systems</td>
<td>Chris (NA)</td>
<td>Active</td>
</tr>
<tr>
<td>Signal to noise</td>
<td>Junji (APAC)</td>
<td>Active</td>
</tr>
<tr>
<td>Peak shape, resolution and selectivity</td>
<td>Stu (EU)</td>
<td>Active</td>
</tr>
<tr>
<td>SST</td>
<td>On hold</td>
<td>In S1</td>
</tr>
<tr>
<td>Data smoothing and peak filtering</td>
<td>Francesca (LA)</td>
<td>Complete</td>
</tr>
<tr>
<td>Internal standard response criteria</td>
<td>Ravi T (APAC)</td>
<td>Pending (also in S1)</td>
</tr>
<tr>
<td>General Integration parameters</td>
<td>Hollie (NA)</td>
<td>Active</td>
</tr>
<tr>
<td>Integration process (automated, semi-automated, manual)</td>
<td>John (NA)</td>
<td>Active</td>
</tr>
<tr>
<td>Reintegration (post regression)</td>
<td>Ravi S (APAC)</td>
<td>Active</td>
</tr>
<tr>
<td>Chromatographic data review</td>
<td>All</td>
<td>On hold (last task)</td>
</tr>
<tr>
<td>Audit Trail</td>
<td>Hollie (NA)</td>
<td>Complete</td>
</tr>
</tbody>
</table>
Next steps

• Complete, agree and issue recommendation for each subtask
• Obtain ‘key’ vendor input where available
• Team completes ‘Chromatographic data review’ task
• Check interdependencies with other ‘S’ teams
• Compile preliminary slidedeck for presentation in Mar
• Solicit feedback from wider audience (e-survey or similar)
• Adjust slidedeck following feedback
Acknowledgements

• The GBC Founding Members
• The GBC Steering Committee
• The Harmonization Team leaders and members
Thank you